When Progress Stalls Weight-loss plateaus are expected, not a failure
Brian Slomovitz, director of gynecologic oncology at Mount Sinai Medical Center in Miami Beach, Florida, was not involved with this study but reacted to the findings in an interview with Fox News Digital
That voice that used to scream for a snack at 3pm now whispers politely and accepts a glass of water as an answer
W.DeOreK
some randomized controlled trials demonstrated that liraglutide, dulaglutide, semaglutide, and albiglutide reduced the rate of CV events in T2DM patients (69), while other clinical trials concluded that lixisenatide and exenatide did not significantly improve CV outcomes in such patients (10, 11)
Blue Crosss move is among the latest signs the surge in demand for GLP-1s, which doctors say provide broad health benefits to their patients, is pushing insurers and employers toward a financial breaking point